Environmental impact of inhaler therapies in a cystic fibrosis unit: Strategies for sustainability.

IF 1 Q4 PHARMACOLOGY & PHARMACY

FARMACIA HOSPITALARIA Pub Date : 2024-12-04 DOI:10.1016/j.farma.2024.07.011

Laura Gómez-Ganda, Beatriz García-Palop, Arnau Mariscal-Puig, Alejandro Ábalos-Camacho, Aurora Fernández-Polo

{"title":"Environmental impact of inhaler therapies in a cystic fibrosis unit: Strategies for sustainability.","authors":"Laura Gómez-Ganda, Beatriz García-Palop, Arnau Mariscal-Puig, Alejandro Ábalos-Camacho, Aurora Fernández-Polo","doi":"10.1016/j.farma.2024.07.011","DOIUrl":null,"url":null,"abstract":"Objective: Inhaled therapy is essential in cystic fibrosis; however, inhalers have a significant environmental impact due to the greenhouse gases (GHGs) emitted. The environmental impact of a product is estimated by its carbon footprint (CF). Pressurized metered-dose inhalers (pMDIs) have a higher CF than dry powder inhalers (DPIs) and soft mist inhalers (SMIs) due to the incorporation of GHGs. The objectives are to analyze the consumption of inhalers (β2-adrenergic agonist bronchodilators, anticholinergics, and/or corticosteroids) in a cystic fibrosis unit and estimate the generated CF.Method: Retrospective determination (January 2018-December 2023) of consumption and CF (tCO2eq) by type of inhaler was conducted. Consumption and CF trends were evaluated using lineal regression.Results: Annually, 1,529 (1,279-1,613) pMDIs, 1,055 (855-1,333) DPIs, and 28 (20-42) SMIs were dispensed, representing 55.97%, 42.33%, and 1.70%, respectively. A statistically significant positive trend in the consumption of SMIs was observed. The median annual CF was: pMDI 38.3 (31.2-40.3) tCO2eq, DPIs 0.8 (0.6-0.9) tCO2eq, and SMIs 0.02 (0.02-0.03) tCO2eq, representing 97.86, 2.04, and 0.10%, respectively.Conclusions: pMDIs were the inhalers with the highest consumption and CF, although their consumption appears to be decreasing, with an increase in the consumption of SMIs.","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA HOSPITALARIA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.farma.2024.07.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Inhaled therapy is essential in cystic fibrosis; however, inhalers have a significant environmental impact due to the greenhouse gases (GHGs) emitted. The environmental impact of a product is estimated by its carbon footprint (CF). Pressurized metered-dose inhalers (pMDIs) have a higher CF than dry powder inhalers (DPIs) and soft mist inhalers (SMIs) due to the incorporation of GHGs. The objectives are to analyze the consumption of inhalers (β2-adrenergic agonist bronchodilators, anticholinergics, and/or corticosteroids) in a cystic fibrosis unit and estimate the generated CF.

Method: Retrospective determination (January 2018-December 2023) of consumption and CF (tCO2eq) by type of inhaler was conducted. Consumption and CF trends were evaluated using lineal regression.

Results: Annually, 1,529 (1,279-1,613) pMDIs, 1,055 (855-1,333) DPIs, and 28 (20-42) SMIs were dispensed, representing 55.97%, 42.33%, and 1.70%, respectively. A statistically significant positive trend in the consumption of SMIs was observed. The median annual CF was: pMDI 38.3 (31.2-40.3) tCO2eq, DPIs 0.8 (0.6-0.9) tCO2eq, and SMIs 0.02 (0.02-0.03) tCO2eq, representing 97.86, 2.04, and 0.10%, respectively.

Conclusions: pMDIs were the inhalers with the highest consumption and CF, although their consumption appears to be decreasing, with an increase in the consumption of SMIs.

查看原文本刊更多论文

囊性纤维化单位吸入器治疗的环境影响：可持续性策略。

目的：吸入治疗囊性纤维化是必要的；然而，吸入器由于排放温室气体而对环境产生重大影响。产品对环境的影响是通过其碳足迹（CF）来估计的。由于温室气体的掺入，加压计量吸入器（pmdi）的CF高于干粉吸入器（DPIs）和软雾吸入器（SMIs）。目的是分析囊性纤维化单位吸入器（β2-肾上腺素能激动剂支气管扩张剂、抗胆碱能药和/或皮质类固醇）的消耗，并估计产生的CF。方法：回顾性测定（2018年1月至2023年12月）按吸入器类型的消耗和CF （tCO2eq）。使用线性回归评估消费和CF趋势。结果：每年发放pmdi 1529（1279 ~ 1613）张，dpi 1055（855 ~ 1333）张，smi 28（20 ~ 42）张，分别占55.97%、42.33%和1.70%。在统计上观察到SMIs的消费有显著的积极趋势。年CF中位数为：pMDI 38.3 (31.2-40.3) tCO2eq, DPIs 0.8 (0.6-0.9) tCO2eq, SMIs 0.02 (0.02-0.03) tCO2eq，分别为97.86、2.04和0.10%。结论：pmdi是消耗和CF最高的吸入器，尽管它们的消耗似乎在减少，但SMIs的消耗在增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

FARMACIA HOSPITALARIA PHARMACOLOGY & PHARMACY-

CiteScore

1.90

自引率

21.40%

发文量

审稿时长

37 days

期刊介绍： Una gran revista para acceder a los mejores artículos originales y revisiones de la farmacoterapia actual. Además, es Órgano de expresión científica de la Sociedad Española de Farmacia Hospitalaria, y está indexada en Index Medicus/Medline, EMBASE/Excerpta Médica, Alert, Internacional Pharmaceutical Abstracts y SCOPUS.